Effects of Cerebrolysin® in Patients With Minimally Conscious State After Stroke: An Observational Retrospective Clinical Study.

Kim JY, Kim HJ, Choi HS, Park SY, Kim DY

Frontiers in neurology2 Aug 2019Cited by 11 (Europe PMC)

PMID31428035PMCIDPMC6687773DOI10.3389/fneur.2019.00803PepBankPUB-31428035

Summary

Introduction: The neurotrophic drug Cerebrolysin is composed of low-molecular-weight peptides and amino acids and has been shown to have neuroprotective and neuroplastic properties. Cerebrolysin has been reported to promote the recovery of motor functions in central nervous system disorders; however, the effects on the consciousness improvements in post-stroke patients have not yet been studied extensively. Therefore, we aimed to examine the effectiveness of Cerebrolysin on improving the consciousness level of stroke patients with minimally conscious state (MCS). Materials and Methods: In this retrospective study we included ischemic and/or hemorrhagic stroke patients with MCS according to the Coma Recovery Scale-Revised (CRS-R), who were admitted to our hospital between 2014 and 2017. All patients received comprehensive rehabilitation therapy including physical and occupational therapy. We compared patients treated with Cerebrolysin against patients who did not receive Cerebrolysin. Patients were included in the verum group if they received 10 mL of Cerebrolysin IV for at least 20 days. CRS-R scores were assessed at admission and discharge. Results: Of 1,531 patients screened, 75 were included in the study (Cerebrolysin, n = 43; control, n = 32). Baseline characteristics were similar between groups. At discharge, ~2 months after onset of stroke, Cerebrolysin-treated patients improved significantly in the CRS-R (p = 0.010) after adjustment for confounders using linear mixed model (LMM), especially in the Oromotor (p = 0.003) and Arousal subscales (p = 0.038). No safety issues were observed. Conclusion: This retrospective study suggests that Cerebrolysin may improve the level of consciousness in stroke patients with MCS, which should be further investigated in a well-designed, double-blind, placebo-controlled, randomized trial.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanObservational studyEfficacy outcome
In stroke patients with minimally conscious state, Cerebrolysin treatment was associated with improved CRS-R scores at discharge after confounder adjustment.
In plain wordsIn stroke patients with minimal consciousness, Cerebrolysin was linked to better consciousness scores than no Cerebrolysin.
Peptide
Cerebrolysin
Outcome
IncreaseCRS-R score at discharge
Study
n = 75
Comparator
Patients who did not receive Cerebrolysin
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
10 mL · IV · at least 20 daysAs given in this study (human).
Measurements
P value for CRS-R improvement
0.01
Cerebrolysin-treated versus untreated patients at discharge, ~2 months after stroke onset, confounder-adjusted linear mixed model
Source sentences
Summary
At discharge, ~2 months after onset of stroke, Cerebrolysin-treated patients improved significantly in the CRS-R (p = 0.010) after adjustment for confounders using linear mixed model (LMM), especially in the Oromotor (p = 0.003) and Arousal subscales (p = 0.038).
3 context sentences(design, population, supporting numbers)
Summary · context
In this retrospective study we included ischemic and/or hemorrhagic stroke patients with MCS according to the Coma Recovery Scale-Revised (CRS-R), who were admitted to our hospital between 2014 and 2017.
Summary · context
We compared patients treated with Cerebrolysin against patients who did not receive Cerebrolysin.
Summary · context
Patients were included in the verum group if they received 10 mL of Cerebrolysin IV for at least 20 days.
Show in the study text Report a problemFND-3142803501
02HumanObservational studyEfficacy outcome
In stroke patients with minimally conscious state, Cerebrolysin treatment was associated with improved Oromotor subscale scores after confounder adjustment.
In plain wordsIn stroke patients with minimal consciousness, Cerebrolysin was linked to better Oromotor scores than no Cerebrolysin.
Peptide
Cerebrolysin
Outcome
IncreaseOromotor subscale
Study
n = 75
Comparator
Patients who did not receive Cerebrolysin
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
10 mL · IV · at least 20 daysAs given in this study (human).
Measurements
P value for Oromotor subscale improvement
0.003
Cerebrolysin-treated versus untreated patients at discharge, ~2 months after stroke onset, confounder-adjusted linear mixed model
Source sentences
Summary
At discharge, ~2 months after onset of stroke, Cerebrolysin-treated patients improved significantly in the CRS-R (p = 0.010) after adjustment for confounders using linear mixed model (LMM), especially in the Oromotor (p = 0.003) and Arousal subscales (p = 0.038).
3 context sentences(design, population, supporting numbers)
Summary · context
In this retrospective study we included ischemic and/or hemorrhagic stroke patients with MCS according to the Coma Recovery Scale-Revised (CRS-R), who were admitted to our hospital between 2014 and 2017.
Summary · context
We compared patients treated with Cerebrolysin against patients who did not receive Cerebrolysin.
Summary · context
Patients were included in the verum group if they received 10 mL of Cerebrolysin IV for at least 20 days.
Show in the study text Report a problemFND-3142803502
03HumanObservational studyEfficacy outcome
In stroke patients with minimally conscious state, Cerebrolysin treatment was associated with improved Arousal subscale scores after confounder adjustment.
In plain wordsIn stroke patients with minimal consciousness, Cerebrolysin was linked to better arousal scores than no Cerebrolysin.
Peptide
Cerebrolysin
Outcome
IncreaseArousal subscale
Study
n = 75
Comparator
Patients who did not receive Cerebrolysin
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
10 mL · IV · at least 20 daysAs given in this study (human).
Measurements
P value for Arousal subscale improvement
0.038
Cerebrolysin-treated versus untreated patients at discharge, ~2 months after stroke onset, confounder-adjusted linear mixed model
Source sentences
Summary
At discharge, ~2 months after onset of stroke, Cerebrolysin-treated patients improved significantly in the CRS-R (p = 0.010) after adjustment for confounders using linear mixed model (LMM), especially in the Oromotor (p = 0.003) and Arousal subscales (p = 0.038).
3 context sentences(design, population, supporting numbers)
Summary · context
In this retrospective study we included ischemic and/or hemorrhagic stroke patients with MCS according to the Coma Recovery Scale-Revised (CRS-R), who were admitted to our hospital between 2014 and 2017.
Summary · context
We compared patients treated with Cerebrolysin against patients who did not receive Cerebrolysin.
Summary · context
Patients were included in the verum group if they received 10 mL of Cerebrolysin IV for at least 20 days.
Show in the study text Report a problemFND-3142803503
04HumanObservational studySafety outcome
In stroke patients with minimally conscious state treated with Cerebrolysin, no safety issues were observed.
In plain wordsIn stroke patients with minimal consciousness treated with Cerebrolysin, the study observed no safety issues.
Peptide
Cerebrolysin
Outcome
Not applicableSafety issues
Study
n = 43
Outcome group
Adverse events · Whole body
Studied dose
10 mL · IV · at least 20 daysAs given in this study (human).
Source sentences
Summary
No safety issues were observed.
3 context sentences(design, population, supporting numbers)
Summary · context
In this retrospective study we included ischemic and/or hemorrhagic stroke patients with MCS according to the Coma Recovery Scale-Revised (CRS-R), who were admitted to our hospital between 2014 and 2017.
Summary · context
We compared patients treated with Cerebrolysin against patients who did not receive Cerebrolysin.
Summary · context
Patients were included in the verum group if they received 10 mL of Cerebrolysin IV for at least 20 days.
Show in the study text Report a problemFND-3142803504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT04751136

the Effect of Cerebrolysin on Physical and Mental Functions of Down Syndrome

Mansoura University Children Hospitaln = 6430 Sept 2016 to 30 Aug 2019

Down Syndrome

Trial page ClinicalTrials.govUpdated 11 Feb 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.